Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo.

[1]  G. Rasmanis,et al.  EFFECTS OF INTERMITTENT TREATMENT WITH ASPIRIN ON THROMBOXANE AND PROSTACYCLIN FORMATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.

[2]  A. Dembińska-kieć,et al.  On the Mechanism of Thrombolytic Action of Thromboxane Synthetase Inhibitors , 1987, Thrombosis and Haemostasis.

[3]  Smith Jb.  Pharmacology of thromboxane synthetase inhibitors. , 1987 .

[4]  F. Fitzpatrick,et al.  Pharmacology of synthetic thromboxane A2. , 1987, Advances in prostaglandin, thromboxane, and leukotriene research.

[5]  G. FitzGerald,et al.  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.

[6]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[7]  P. Henriksson,et al.  In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. , 1986, British heart journal.

[8]  K. Gréen,et al.  In vivo synthesis of thromboxane and prostacyclin in man in health and disease. Data from GC-MS measurements of major urinary metabolites. , 1986, Advances in prostaglandin, thromboxane, and leukotriene research.

[9]  P. Henriksson,et al.  In vivo production of thromboxane in acute human myocardial infarction: a preliminary study. , 1985, Thrombosis research.

[10]  K. Gréen,et al.  Development of a GC-MS method for quantitation of 2,3-dinor-6-keto-PGF1 alpha and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. , 1984, Prostaglandins.

[11]  G. FitzGerald,et al.  Selective and nonselective inhibition of thromboxane formation , 1984, Clinical pharmacology and therapeutics.

[12]  K. Gréen,et al.  Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. , 1984, Prostaglandins.

[13]  O. Sebek,et al.  Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. , 1984, Thrombosis research.

[14]  C. Bernutz,et al.  The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. , 1983, Circulation.

[15]  A. Marcus,et al.  Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. , 1980, The Journal of clinical investigation.